Cytosolic DNA sensor cGAS plays an essential pathogenetic role in pressure overload-induced heart failure

Abstract
Background: Growing evidence shows that activation of inflammation in the heart provokes left ventricular (LV) remodeling and dysfunction in humans and experimental animals with heart failure (HF). Moreover, recent studies found that cyclic GMP-AMP synthase (cGAS), serving as a cytosolic DNA sensor, was essential for activating innate immunity against infection and cellular damage by initiating the STING-IRFs-type I IFN signaling cascade, which played important roles in regulating the inflammatory response. However, the pathophysiological role of cGAS in pressure overload-induced HF is unclear. Methods:Wild-type C57BL/6J mice and cGAS inhibition mice were subjected to transverse aortic constriction (TAC) to induce HF or sham operation. Inhibition of cGAS in the murine heart was performed using adeno-associated virus 9 (AAV9). Alterations of the cGAS/STING pathway were examined by qPCR and Western blotting. Cardiac remodeling was assessed by echocardiography as well as histological and molecular phenotyping. Results:Compared with sham-operated mice, the cGAS/STING pathway was activated in LV tissues in TAC mice. While TAC mice exhibited significant pathological cardiac remodeling and LV dysfunction, inhibition of cGAS improved early survival rates after TAC, preserved LV contractile function and blunted pathological remodeling, including cardiac hypertrophy, fibrosis and apoptosis. Furthermore, downregulation of cGAS diminished early inflammatory cells infiltration and inflammatory cytokines expression in response to TAC. Conclusions: These results demonstrated that cGAS played an essential pathogenetic role in pressure overload-induced HF to promote pathological cardiac remodeling and dysfunction. Our results suggest that inhibition of cGAS may be a novel therapeutic approach for HF.
Funding Information
  • National Natural Science Foundation of China (81770356, 81470473)
  • Capital Health Research and Development of Special (2016-2-4083)